{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:08:18Z","timestamp":1784214498338,"version":"3.55.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","award":["Program anti-COVID-19 Misure Urgenti in materia di contenimento e gestione della emergenza epidemiologica da COVID-19 DRG N.140\/2020"],"award-info":[{"award-number":["Program anti-COVID-19 Misure Urgenti in materia di contenimento e gestione della emergenza epidemiologica da COVID-19 DRG N.140\/2020"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has unpredictable manifestations of coronavirus disease (COVID-19) and variable clinical course with some patients being asymptomatic whereas others experiencing severe respiratory distress, or even death. We aimed to evaluate the immunoglobulin G (IgG) response towards linear peptides on a peptide array containing sequences from SARS-CoV-2, Middle East respiratory syndrome-related coronavirus (MERS) and common-cold coronaviruses 229E, OC43, NL63 and HKU1 antigens, in order to identify immunological indicators of disease outcome in SARS-CoV-2 infected patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included in the study 79 subjects, comprising 19 pediatric and 30 adult SARS-CoV-2 infected patients with increasing disease severity, from mild to critical illness, and 30 uninfected subjects who were vaccinated with one dose of SARS-CoV-2 spike mRNA BNT162b2 vaccine. Serum samples were analyzed by a peptide microarray containing 5828 overlapping 15-mer synthetic peptides corresponding to the full SARS-CoV-2 proteome and selected linear epitopes of spike (S), envelope (E) and membrane (M) glycoproteins as well as nucleoprotein (N) of MERS, SARS and coronaviruses 229E, OC43, NL63 and HKU1 (isolates 1, 2 and 5).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All patients exhibited high IgG reactivity against the central region and C-terminus peptides of both SARS-CoV-2 N and S proteins. Setting the threshold value for serum reactivity above 25,000 units, 100% and 81% of patients with severe disease, 36% and 29% of subjects with mild symptoms, and 8% and 17% of children younger than 8-years reacted against N and S proteins, respectively. Overall, the total number of peptides in the SARS-CoV-2 proteome targeted by serum samples was much higher in children compared to adults. Notably, we revealed a differential antibody response to SARS-CoV-2 peptides of M protein between adults, mainly reacting against the C-terminus epitopes, and children, who were highly responsive to the N-terminus of M protein. In addition, IgG signals against NS7B, NS8 and ORF10 peptides were found elevated mainly among adults with mild (63%) symptoms. Antibodies towards S and N proteins of other coronaviruses (MERS, 229E, OC43, NL63 and HKU1) were detected in all groups without a significant correlation with SARS-CoV-2 antibody levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overall, our results showed that antibodies elicited by specific linear epitopes of SARS-CoV-2 proteome are age dependent and related to COVID-19 clinical severity. Cross-reaction of antibodies to epitopes of other human coronaviruses was evident in all patients with distinct profiles between children and adult patients. Several SARS-CoV-2 peptides identified in this study are of particular interest for the development of vaccines and diagnostic tests to predict the clinical outcome of SARS-CoV-2 infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-03963-5","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T16:19:44Z","timestamp":1676909984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0972-5668","authenticated-orcid":false,"given":"Anna Lucia","family":"Tornesello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Micillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Labonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Isgr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Meola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesta","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Nicastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Atripaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemy","family":"Starita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cerasuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlo","family":"Holenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Buonaguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco M.","family":"Buonaguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lina","family":"Tornesello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"issue":"3","key":"3963_CR1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V'Kovski","year":"2021","unstructured":"V\u2019Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155\u201370.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"3963_CR2","volume":"12","author":"M Pal","year":"2020","unstructured":"Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12(3): e7423.","journal-title":"Cureus"},{"key":"3963_CR3","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2147\/IDR.S306441","volume":"14","author":"S Alsobaie","year":"2021","unstructured":"Alsobaie S. Understanding the molecular biology of SARS-CoV-2 and the COVID-19 pandemic: a review. Infect Drug Resist. 2021;14:2259\u201368.","journal-title":"Infect Drug Resist"},{"issue":"5","key":"3963_CR4","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2134","volume":"30","author":"FM Buonaguro","year":"2020","unstructured":"Buonaguro FM, Ascierto PA, Morse GD, Buonaguro L, Puzanov I, Tornesello ML, Brechot C, Gallo RC. Covid-19: time for a paradigm change. Rev Med Virol. 2020;30(5): e2134.","journal-title":"Rev Med Virol"},{"issue":"8","key":"3963_CR5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/0020764020942247","volume":"66","author":"K Poudel","year":"2020","unstructured":"Poudel K, Subedi P. Impact of COVID-19 pandemic on socioeconomic and mental health aspects in Nepal. Int J Soc Psychiatry. 2020;66(8):748\u201355.","journal-title":"Int J Soc Psychiatry"},{"key":"3963_CR6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-micro-020518-115759","volume":"73","author":"TS Fung","year":"2019","unstructured":"Fung TS, Liu DX. Human coronavirus: host-pathogen interaction. Annu Rev Microbiol. 2019;73:529\u201357.","journal-title":"Annu Rev Microbiol"},{"issue":"11","key":"3963_CR7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","volume":"19","author":"H Yang","year":"2021","unstructured":"Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol. 2021;19(11):685\u2013700.","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"3963_CR8","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1038\/s41401-021-00851-w","volume":"43","author":"CR Wu","year":"2022","unstructured":"Wu CR, Yin WC, Jiang Y, Xu HE. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Acta Pharmacol Sin. 2022;43(12):3021\u201333.","journal-title":"Acta Pharmacol Sin"},{"issue":"7816","key":"3963_CR9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O\u2019Meara MJ, Rezelj VV, Guo JZ, Swaney DL, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459\u201368.","journal-title":"Nature"},{"key":"3963_CR10","doi-asserted-by":"crossref","first-page":"708264","DOI":"10.3389\/fimmu.2021.708264","volume":"12","author":"N Redondo","year":"2021","unstructured":"Redondo N, Zaldivar-Lopez S, Garrido JJ, Montoya M. SARS-CoV-2 accessory proteins in viral pathogenesis: knowns and unknowns. Front Immunol. 2021;12:708264.","journal-title":"Front Immunol"},{"key":"3963_CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virusres.2014.03.018","volume":"194","author":"B Meyer","year":"2014","unstructured":"Meyer B, Drosten C, Muller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 2014;194:175\u201383.","journal-title":"Virus Res"},{"issue":"1","key":"3963_CR12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2022","unstructured":"Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3\u201320.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"3963_CR13","doi-asserted-by":"crossref","first-page":"16944","DOI":"10.1038\/s41598-020-74101-0","volume":"10","author":"M Ord","year":"2020","unstructured":"Ord M, Faustova I, Loog M. The sequence at Spike S1\/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV. Sci Rep. 2020;10(1):16944.","journal-title":"Sci Rep"},{"key":"3963_CR14","doi-asserted-by":"crossref","first-page":"594495","DOI":"10.3389\/fmed.2020.594495","volume":"7","author":"F Salamanna","year":"2020","unstructured":"Salamanna F, Maglio M, Landini MP, Fini M. Body localization of ACE-2: on the trail of the keyhole of SARS-CoV-2. Front Med (Lausanne). 2020;7:594495.","journal-title":"Front Med (Lausanne)"},{"issue":"7807","key":"3963_CR15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215\u201320.","journal-title":"Nature"},{"key":"3963_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abc8413","author":"L Premkumar","year":"2020","unstructured":"Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L, Weiss S, Park Y, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020. https:\/\/doi.org\/10.1126\/sciimmunol.abc8413.","journal-title":"Sci Immunol"},{"issue":"4","key":"3963_CR17","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C, Pinto D, Rosen LE, Bowen JE, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024-1042 e1021.","journal-title":"Cell"},{"issue":"4","key":"3963_CR18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","volume":"14","author":"I Astuti","year":"2020","unstructured":"Astuti I, Ysrafil. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab Syndr. 2020;14(4):407\u201312.","journal-title":"Diabetes Metab Syndr"},{"issue":"13","key":"3963_CR19","doi-asserted-by":"crossref","first-page":"108915","DOI":"10.1016\/j.celrep.2021.108915","volume":"34","author":"Y Li","year":"2021","unstructured":"Li Y, Ma ML, Lei Q, Wang F, Hong W, Lai DY, Hou H, Xu ZW, Zhang B, Chen H, et al. Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. Cell Rep. 2021;34(13):108915.","journal-title":"Cell Rep"},{"issue":"5","key":"3963_CR20","doi-asserted-by":"crossref","first-page":"e106228","DOI":"10.15252\/embj.2020106228","volume":"40","author":"SL Caddy","year":"2021","unstructured":"Caddy SL, Vaysburd M, Papa G, Wing M, O\u2019Connell K, Stoycheva D, Foss S, Terje Andersen J, Oxenius A, James LC. Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity. EMBO J. 2021;40(5):e106228.","journal-title":"EMBO J"},{"issue":"1","key":"3963_CR21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12879-021-05786-5","volume":"21","author":"M Girona-Alarcon","year":"2021","unstructured":"Girona-Alarcon M, Bobillo-Perez S, Sole-Ribalta A, Hernandez L, Guitart C, Suarez R, Balaguer M, Cambra FJ, Jordan I, Group KI-Cs, et al. The different manifestations of COVID-19 in adults and children: a cohort study in an intensive care unit. BMC Infect Dis. 2021;21(1):87.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"3963_CR22","doi-asserted-by":"crossref","first-page":"530","DOI":"10.47102\/annals-acadmedsg.2020257","volume":"49","author":"J Li","year":"2020","unstructured":"Li J, Thoon KC, Chong CY, Maiwald M, Kam KQ, Nadua K, Tan NW, Yung CF. Comparative analysis of symptomatic and asymptomatic SARS-CoV-2 infection in children. Ann Acad Med Singap. 2020;49(8):530\u20137.","journal-title":"Ann Acad Med Singap"},{"key":"3963_CR23","doi-asserted-by":"crossref","first-page":"741796","DOI":"10.3389\/fimmu.2021.741796","volume":"12","author":"MR Petrara","year":"2021","unstructured":"Petrara MR, Bonfante F, Costenaro P, Cantarutti A, Carmona F, Ruffoni E, Di Chiara C, Zanchetta M, Barzon L, Dona D, et al. Asymptomatic and mild SARS-CoV-2 infections elicit lower immune activation and higher specific neutralizing antibodies in children than in adults. Front Immunol. 2021;12:741796.","journal-title":"Front Immunol"},{"key":"3963_CR24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jim.2014.11.006","volume":"416","author":"KE Stephenson","year":"2015","unstructured":"Stephenson KE, Neubauer GH, Reimer U, Pawlowski N, Knaute T, Zerweck J, Korber BT, Barouch DH. Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. J Immunol Methods. 2015;416:105\u201323.","journal-title":"J Immunol Methods"},{"issue":"1","key":"3963_CR25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-1759(02)00137-0","volume":"267","author":"R Frank","year":"2002","unstructured":"Frank R. The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports\u2013principles and applications. J Immunol Methods. 2002;267(1):13\u201326.","journal-title":"J Immunol Methods"},{"issue":"7","key":"3963_CR26","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/eji.202049101","volume":"51","author":"P Holenya","year":"2021","unstructured":"Holenya P, Lange PJ, Reimer U, Woltersdorf W, Panterodt T, Glas M, Wasner M, Eckey M, Drosch M, Hollidt JM, et al. Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development. Eur J Immunol. 2021;51(7):1839\u201349.","journal-title":"Eur J Immunol"},{"key":"3963_CR27","doi-asserted-by":"crossref","first-page":"574541","DOI":"10.3389\/fendo.2020.574541","volume":"11","author":"J Chen","year":"2020","unstructured":"Chen J, Wu C, Wang X, Yu J, Sun Z. The impact of COVID-19 on blood glucose: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2020;11:574541.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"3963_CR28","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/jmv.27556","volume":"94","author":"F Xiao","year":"2022","unstructured":"Xiao F, Zhou YC, Zhang MB, Chen D, Peng SL, Tang HN, Li L, Tang CY, Liu JY, Li B, et al. Hyperglycemia and blood glucose deterioration are risk factors for severe COVID-19 with diabetes: a two-center cohort study. J Med Virol. 2022;94(5):1967\u201375.","journal-title":"J Med Virol"},{"issue":"7","key":"3963_CR29","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205\u201311.","journal-title":"Nat Med"},{"issue":"10283","key":"3963_CR30","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(21)00675-9","volume":"397","author":"VJ Hall","year":"2021","unstructured":"Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, Wellington E, Cole MJ, Saei A, Oguti B, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397(10283):1459\u201369.","journal-title":"Lancet"},{"issue":"2","key":"3963_CR31","doi-asserted-by":"crossref","first-page":"109822","DOI":"10.1016\/j.celrep.2021.109822","volume":"37","author":"AK Wheatley","year":"2021","unstructured":"Wheatley AK, Pymm P, Esterbauer R, Dietrich MH, Lee WS, Drew D, Kelly HG, Chan LJ, Mordant FL, Black KA, et al. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. Cell Rep. 2021;37(2):109822.","journal-title":"Cell Rep"},{"issue":"6","key":"3963_CR32","first-page":"CD014945","volume":"6","author":"C Hirsch","year":"2022","unstructured":"Hirsch C, Park YS, Piechotta V, Chai KL, Estcourt LJ, Monsef I, Salomon S, Wood EM, So-Osman C, McQuilten Z, et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database Syst Rev. 2022;6(6):CD014945.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"3963_CR33","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","volume":"130","author":"EM Bloch","year":"2020","unstructured":"Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757\u201365.","journal-title":"J Clin Invest"},{"key":"3963_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering9020072","author":"D Kudlay","year":"2022","unstructured":"Kudlay D, Svistunov A. COVID-19 vaccines: an overview of different platforms. Bioengineering (Basel). 2022. https:\/\/doi.org\/10.3390\/bioengineering9020072.","journal-title":"Bioengineering (Basel)"},{"issue":"2","key":"3963_CR35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, Hauser BM, Caradonna TM, Clayton KL, Nitido AD, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476-488 e411.","journal-title":"Cell"},{"issue":"3","key":"3963_CR36","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2020.07.020","volume":"53","author":"C Atyeo","year":"2020","unstructured":"Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, McCulloch DJ, Newman KL, Wolf C, Yu J, et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity. 2020;53(3):524\u201332.","journal-title":"Immunity"},{"issue":"1","key":"3963_CR37","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s42003-020-01526-8","volume":"3","author":"L Ren","year":"2020","unstructured":"Ren L, Zhang L, Chang D, Wang J, Hu Y, Chen H, Guo L, Wu C, Wang C, Wang Y, et al. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Commun Biol. 2020;3(1):780.","journal-title":"Commun Biol"},{"key":"3963_CR38","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02940-20","author":"JJ Guthmiller","year":"2021","unstructured":"Guthmiller JJ, Stovicek O, Wang J, Changrob S, Li L, Halfmann P, Zheng NY, Utset H, Stamper CT, Dugan HL, et al. SARS-CoV-2 infection severity is linked to superior humoral immunity against the Spike. MBio. 2021. https:\/\/doi.org\/10.1128\/mBio.02940-20.","journal-title":"MBio"},{"key":"3963_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.148855","author":"C Voss","year":"2021","unstructured":"Voss C, Esmail S, Liu X, Knauer MJ, Ackloo S, Kaneko T, Lowes L, Stogios P, Seitova A, Hutchinson A, et al. Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern. JCI Insight. 2021. https:\/\/doi.org\/10.1172\/jci.insight.148855.","journal-title":"JCI Insight"},{"issue":"1","key":"3963_CR40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41590-020-00826-9","volume":"22","author":"SP Weisberg","year":"2021","unstructured":"Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin WH, Wontakal S, Szabo PA, Wells SB, Dogra P, Gray J, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. 2021;22(1):25\u201331.","journal-title":"Nat Immunol"},{"issue":"5","key":"3963_CR41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41423-020-0377-z","volume":"17","author":"G Lucchese","year":"2020","unstructured":"Lucchese G. Epitopes for a 2019-nCoV vaccine. Cell Mol Immunol. 2020;17(5):539\u201340.","journal-title":"Cell Mol Immunol"},{"key":"3963_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4250","author":"E Shrock","year":"2020","unstructured":"Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, Robinson ML, Sie BM, Li MZ, Chen Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020. https:\/\/doi.org\/10.1126\/science.abd4250.","journal-title":"Science"},{"issue":"6","key":"3963_CR43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845\u20138.","journal-title":"Nat Med"},{"key":"3963_CR44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2021.113197","volume":"500","author":"A Manenti","year":"2022","unstructured":"Manenti A, Gianchecchi E, Dapporto F, Leonardi M, Cantaloni P, Fattorini F, Piu P, Bollati V, Pastorino U, Apolone G, et al. Evaluation and correlation between SARS-CoV-2 neutralizing and binding antibodies in convalescent and vaccinated subjects. J Immunol Methods. 2022;500: 113197.","journal-title":"J Immunol Methods"},{"issue":"1","key":"3963_CR45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13027-022-00451-1","volume":"17","author":"MA Isgro","year":"2022","unstructured":"Isgro MA, Trillo G, Russo L, Tornesello AL, Buonaguro L, Tornesello ML, Miscio L, Normanno N, Bianchi AAM, Buonaguro FM, et al. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS \u201cFondazione Pascale\u201d Cancer Center (Naples, Italy). Infect Agent Cancer. 2022;17(1):40.","journal-title":"Infect Agent Cancer"},{"issue":"4","key":"3963_CR46","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jinf.2021.08.012","volume":"83","author":"N Allen","year":"2021","unstructured":"Allen N, Brady M, Carrion Martin AI, Domegan L, Walsh C, Doherty L, Riain UN, Bergin C, Fleming C, Conlon N. Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals. J Infect. 2021;83(4):e9\u201310.","journal-title":"J Infect"},{"issue":"1","key":"3963_CR47","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1038\/s41467-022-30699-5","volume":"13","author":"A Hachim","year":"2022","unstructured":"Hachim A, Gu H, Kavian O, Mori M, Kwan MYW, Chan WH, Yau YS, Chiu SS, Tsang OTY, Hui DSC, et al. SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. Nat Commun. 2022;13(1):2951.","journal-title":"Nat Commun"},{"key":"3963_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-022-02163-z","author":"MG Silva","year":"2022","unstructured":"Silva MG, Falcoff NL, Corradi GR, Di Camillo N, Seguel RF, Tabaj GC, Guman GR, de Matteo E, Nunez M, Gironacci MM. Effect of age on human ACE2 and ACE2-expressing alveolar type II cells levels. Pediatr Res. 2022. https:\/\/doi.org\/10.1038\/s41390-022-02163-z.","journal-title":"Pediatr Res"},{"issue":"1","key":"3963_CR49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/infdis\/jiaa161","volume":"222","author":"AS Monto","year":"2020","unstructured":"Monto AS, DeJonge PM, Callear AP, Bazzi LA, Capriola SB, Malosh RE, Martin ET, Petrie JG. Coronavirus occurrence and transmission over 8 years in the HIVE Cohort of households in Michigan. J Infect Dis. 2020;222(1):9\u201316.","journal-title":"J Infect Dis"},{"issue":"2","key":"3963_CR50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41590-021-01123-9","volume":"23","author":"J Chou","year":"2022","unstructured":"Chou J, Thomas PG, Randolph AG. Immunology of SARS-CoV-2 infection in children. Nat Immunol. 2022;23(2):177\u201385.","journal-title":"Nat Immunol"},{"issue":"3","key":"3963_CR51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41587-021-01037-9","volume":"40","author":"J Loske","year":"2022","unstructured":"Loske J, Rohmel J, Lukassen S, Stricker S, Magalhaes VG, Liebig J, Chua RL, Thurmann L, Messingschlager M, Seegebarth A, et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat Biotechnol. 2022;40(3):319\u201324.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"3963_CR52","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41423-020-00523-5","volume":"17","author":"Y Li","year":"2020","unstructured":"Li Y, Lai DY, Zhang HN, Jiang HW, Tian X, Ma ML, Qi H, Meng QF, Guo SJ, Wu Y, et al. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol. 2020;17(10):1095\u20137.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"3963_CR53","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1080\/21505594.2022.2073025","volume":"13","author":"DJ Gregory","year":"2022","unstructured":"Gregory DJ, Vannier A, Duey AH, Roady TJ, Dzeng RK, Pavlovic MN, Chapin MH, Mukherjee S, Wilmot H, Chronos N, et al. Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19. Virulence. 2022;13(1):890\u2013902.","journal-title":"Virulence"},{"key":"3963_CR54","doi-asserted-by":"crossref","first-page":"102911","DOI":"10.1016\/j.ebiom.2020.102911","volume":"58","author":"SN Amrun","year":"2020","unstructured":"Amrun SN, Lee CY, Lee B, Fong SW, Young BE, Chee RS, Yeo NK, Torres-Ruesta A, Carissimo G, Poh CM, et al. Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine. 2020;58:102911.","journal-title":"EBioMedicine"},{"issue":"1","key":"3963_CR55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s42003-021-01743-9","volume":"4","author":"N Mishra","year":"2021","unstructured":"Mishra N, Huang X, Joshi S, Guo C, Ng J, Thakkar R, Wu Y, Dong X, Li Q, Pinapati RS, et al. Immunoreactive peptide maps of SARS-CoV-2. Commun Biol. 2021;4(1):225.","journal-title":"Commun Biol"},{"key":"3963_CR56","doi-asserted-by":"crossref","first-page":"586984","DOI":"10.3389\/fimmu.2020.586984","volume":"11","author":"PA Reche","year":"2020","unstructured":"Reche PA. Potential cross-reactive immunity to SARS-CoV-2 from common human pathogens and vaccines. Front Immunol. 2020;11:586984.","journal-title":"Front Immunol"},{"issue":"11","key":"3963_CR57","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41590-021-01051-8","volume":"22","author":"S Ravichandran","year":"2021","unstructured":"Ravichandran S, Tang J, Grubbs G, Lee Y, Pourhashemi S, Hussaini L, Lapp SA, Jerris RC, Singh V, Chahroudi A, et al. SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19. Nat Immunol. 2021;22(11):1452\u201364.","journal-title":"Nat Immunol"},{"issue":"6522","key":"3963_CR58","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.abe1107","volume":"370","author":"KW Ng","year":"2020","unstructured":"Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C, Wrobel AG, Benton DJ, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339\u201343.","journal-title":"Science"},{"issue":"2","key":"3963_CR59","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.immuni.2021.01.008","volume":"54","author":"A Bonifacius","year":"2021","unstructured":"Bonifacius A, Tischer-Zimmermann S, Dragon AC, Gussarow D, Vogel A, Krettek U, Godecke N, Yilmaz M, Kraft ARM, Hoeper MM, et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 2021;54(2):340-354 e346.","journal-title":"Immunity"},{"issue":"1","key":"3963_CR60","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1038\/s41467-020-18450-4","volume":"11","author":"AT Huang","year":"2020","unstructured":"Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, Borgert BA, Moreno CA, Solomon BD, Trimmer-Smith L, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11(1):4704.","journal-title":"Nat Commun"},{"issue":"9","key":"3963_CR61","doi-asserted-by":"crossref","first-page":"107725","DOI":"10.1016\/j.celrep.2020.107725","volume":"31","author":"H Lv","year":"2020","unstructured":"Lv H, Wu NC, Tsang OT, Yuan M, Perera R, Leung WS, So RTY, Chan JMC, Yip GK, Chik TSH, et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 2020;31(9):107725.","journal-title":"Cell Rep"},{"issue":"1","key":"3963_CR62","doi-asserted-by":"crossref","first-page":"100189","DOI":"10.1016\/j.xcrm.2020.100189","volume":"2","author":"JT Ladner","year":"2021","unstructured":"Ladner JT, Henson SN, Boyle AS, Engelbrektson AL, Fink ZW, Rahee F, D\u2019Ambrozio J, Schaecher KE, Stone M, Dong W, et al. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep Med. 2021;2(1):100189.","journal-title":"Cell Rep Med"},{"issue":"2","key":"3963_CR63","doi-asserted-by":"crossref","first-page":"e0141621","DOI":"10.1128\/Spectrum.01416-21","volume":"9","author":"D Camerini","year":"2021","unstructured":"Camerini D, Randall AZ, Trappl-Kimmons K, Oberai A, Hung C, Edgar J, Shandling A, Huynh V, Teng AA, Hermanson G, et al. Mapping SARS-CoV-2 antibody epitopes in COVID-19 patients with a multi-coronavirus protein microarray. Microbiol Spectr. 2021;9(2):e0141621.","journal-title":"Microbiol Spectr"},{"issue":"13","key":"3963_CR64","doi-asserted-by":"crossref","first-page":"2001782","DOI":"10.2807\/1560-7917.ES.2021.26.13.2001782","volume":"26","author":"I Sermet-Gaudelus","year":"2021","unstructured":"Sermet-Gaudelus I, Temmam S, Huon C, Behillil S, Gajdos V, Bigot T, Lurier T, Chretien D, Backovic M, Delaunay-Moisan A, et al. Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020. Euro Surveill. 2021;26(13):2001782.","journal-title":"Euro Surveill"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03963-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-03963-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03963-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T08:08:40Z","timestamp":1680682120000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-03963-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3963"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-03963-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"3 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Ethics Committee approved the study, performed under the statements of Declaration of Helsinki, document #34\/21 \u201cRUI-SARS\u201d (16\/06\/21).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Ulf Reimer, Pavlo Holenya and Tobias Knaute are employed by JPT Peptide Technologies GmbH. The commercial affiliation (JPT Peptide Technologies GmbH) does not alter the authors' adherence to the journal policies on sharing data and materials. The remaining authors have not conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}